|Ut oh! Lpath Suspends Dosing of iSONEP in Clinical Trials|
|Friday, 27 January 2012 09:13|
Although Lpath believes it has taken appropriate steps to oversee Formatech's manufacturing in order to ensure product quality, it has suspended dosing as a precaution to ensure the continued safety of all patients in its clinical trials. iSONEP was well tolerated by all patients in the Phase 1 trial and by all patients thus far in the PEDigree and Nexus trials. The company has received no claims raising safety concerns regarding iSONEP.
Earlier this week, MarketScanners had called a top to the trading action on the stock from a technical perspective and had advised our premium subscribers first and subsequently others to take profits and close out their positions in the stock. In addtion to several bearish technical indicators, David Ibrahim warned traders that: "In addition to everything else, the company has filed a registration statement to raise up to $10 million through the sale of units comprised of common shares and warrants to purchase common shares. Why wait to be hit with dilution? Wait it out with money in your pockets instead."
Others had continued singing the company's praises in recent days and many had anticipated that 2012 would be a break-out year for the firm. That momentum has certainly been broken by this news and until we learn more, that future seems a little cloudy.
Scott Pancoast, Lpath's president and chief executive officer, commented: "While we are disappointed to learn about these FDA concerns, we believe this issue does not affect the prospects for value creation by our PEDigree and Nexus studies."
"We continue to expect that the resolution of RPE detachments that we saw in each of the two patients in our Phase 1 trial will be repeated in our PEDigree study, and that the significant reductions in lesion size that we also saw in the Phase 1 trial will be repeated in the Nexus study," added Pancoast.
Lpath will be holding a conference this morning at 8:45 a.m. Eastern time to discuss today's news and the company's outlook for 2012.
Details about that call here.